Beijing Municipal Science & Technology Commission Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2013
NCT02542306
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Beijing Municipal Science & Technology Commission

Active Ingredients

Drugs in Phase 2 Trials (2)

fibrinogen (human) (RiaSTAP) (1 trial)

sirolimus (rapamune) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aortic Dissection (Phase 2)

Lupus Erythematosus, Systemic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2